Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: A quantitative angiographic and hematologic study  by Popma, Jeffrey J. et al.
Pennsylvania, and Salt Lake City. Utah 
respectively, at 7 days, p = 0.22). In= 
reccelusion rates were less en& receiving combi- 
To achieve both rapid infarct-related artery recanalization 
typically associated with fibrin-specific thrombolytic agents 
(such as recombinant tissue-type plasminogen activator 
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[rt-PA]) and sustained arterial patency frequently attributed 
to nonspecific thrombolytic agents (such as urokinase), 
combiuation thrombolytic therapy has been used as an 
alternative to monotherapy in patients with acute myocardial 
infarction (1-3). Compared with monotherapy, combination 
thrombolytic therapy has been associated with lower in- 
hospital clinical event and reocclusion rates, although 
!?O-min farct-related artery patency and recovery of ven- 
tricular function appear similar with combination therapy 
and monotherapy regimens (1). 
Two potential factors may be responsible for the reduced 
rates of in-hospital clinical events and reocclusion associated 
with combination thrombolytic therapy. Fist, compared 
with monotherapy, combination thrombolytic therapy may 
enhance clot lysis, thereby resulting in a lower residual 
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thrombus burden and a less avid substrate for recurrent 
Fl_zge]et qgegation and reocclusicn. Alternatively, combi- 
nation thrombolytic herapy may produce more pronounced 
alterations of hemostatic protein variables, culminating in
fibrinogen depletion, elevation of fibrinogen degradation 
products and reduced platelet aggregability. Sustained alter- 
ation of the favorable hemostatic protein milieu may allow 
stabilization f the fibrin-plaque s gment, thereby prevent- 
ing reocclusion. 
To lend insight into the mechanisms responsible for the 
beneficial effects associated with combination thrombolytic 
therapy, infarct-related quantitative coronary dimensions 
were evaluated in 287 patients with acute myocardial infarc- 
tion during the early (90-min) and convalescent (7-day) 
phases after administration f rt-PA, urokinase or a combi- 
nation t-t-PA and urokinase. Hemostatic protein levels were 
also monitored uring the 1st 24 h after treatment. The 
relations among infarct-related residual coronary dimen- 
sions, hemostatic variables and in-hospital c inic.1 events 
and reocclusion were examined. 
Patrent s&&n. In t lysis and Angioplasty in
Myocardial Infarction (TAMIS trial) (l), 575 patients with 
acute myocardial infarction admitted to seven regional car- 
diDlogy centers were randomized ina 3 x 2 factorial design 
to one of three thrombolytic regimens (&PA, urokinase or 
combination rt-PA and urokinase) and to immediate cardiac 
catheterization with “rescue angioplasty,” if indicated, or to 
delayed catheterization. Inclusion criteria included 1) symp 
toms compatible with acute myocardial infarction of 56 h 
duration, 2) ~0.1 mV ST segment elevation i two or more 
contiguous leads, and 3) age <76 years. Patients with 
contraindications to thrombolytic therapy such as prior 
stroke, recent rauma or surgery, refractory hypertension, 
active bleeding, cardiopulmonary resuscitation for>lO min. 
prior coronary bypass urgery, prior Q wave infarction or 
cardiogenic shock were excluded. Thrombolytic treatment 
imens included 1) r&PA (Activase, Genentech; 1 
3 h I60 mg 1st h with a dmg bolus and 20 mg/h for 2 h]; 
2) urokinase (Abbokinase, Abbott Laboratories; 1.5 mU 
boluS and 1.5 mU infusion for 1 h); or 3) combination rt-PA 
(I milks body weight, and urokinase, 1.5 mU for 1 h). 
Unless contraindicated, all patients received aspirin 
(325 mS), heparin (5,000 Ubolus and an infusion of 1,000 U/h 
for 48 h adjusted to maintain the activated partial thrombo- 
PlaStiu time to 1.5 to 2 times normal) and diltiazem (30 to 
60 mg 3 times/day). Nitrates and angiotensin-converting 
enzyme inhibitors were used only if clinically indicated. The 
Protocol was approved by the Institutional Review Board at 
each of the clinical sites. 
SKY groUP (Ftg. 1). This report includes the 287 patients 
who were randomly assigned toearly (90-min) arteriography 
afkf treatment with rt-PA, urokinase or combination t$PA 
and urokinase. Early catheterization was not performed in5 
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Figure 1. Schematic representation of patients randomized to 
Xl-min and ‘I-day ~e~o~rapby after treatment with recombinant 
tissue-type piasminogen activator (&PA), urokinase or combination 
it-PA and urokinase. CABG = coronary bypass surgery; PTCA = 
coronary angioplasty; TAMI = Thrombolysis and Angioplasty in 
Myocardial Infarction, 
patients because of patient or physician refusal in 3 cases; 
death in 1 case and other complications in 1, and the study 
was technically insufficient for quantitative analysis in an 
additional 10 patients. Convalescent arteriography was per- 
formed 7 days after thrombolytic treatment in 176 patients; 
in the absence of intercurrent ischemic events (coronary 
angioplasty in 48 patients; emergency oronary bypass aur- 
get-y in 38 and death in 3); other complications in 4, or patient 
or physician refusal in 3. 
Cardiac atheterization. Cardiac atheterization was gen- 
erally performed from the right or left femoral artery by 
using SF or 6F Judkins catheters unless peripheral vessel 
tortuosity mandated use of larger catheters or “rescue” 
coronary angioplasty was performed. Cineangiograms of the 
infarct-related artery were obtained in two or more ortbog- 
onal projections and infarct-related artery patency was de- 
termined by using the Thrombolysis In Myocardial Infarc- 
tion (TIMI) criteria (4). Both coronary angiography and 
contrast ventriculography were technically adequate for 
quantitative analysis in 197 patients during the 90-min phase 
and in 150 patients during the 7-day phase. 
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raphic Laboratory, w 
tive coronary analysis was perform 
had no knowledge of the clinical 
strating the infarct-related artery stenosis in its most severe 
projection were digitized using a tine-video converter. An 
automated edge detection a~goritbm was ap to the 
digitized image and the arterial contour was rmined. 
With use of the diagnostic coronary catheter as the reference 
diameter, the absolute minimal lumen diameter of a user- 
defined normal and a stenotic segment were determined. The 
sesidual minimal lumen diameter was use 
lion of the degree of clot dissolution i the 90-min arPd 7-day 
phases (6). A minimal umen diameter of 0.0 mm was 
assigned to patients with total occlusion, and a minimal 
lumen diameier was not imputed for patients who under went 
coronary bypass urgery or for whom follow-up angiograms 
were not available. 1 disease was d as two 
or more epicardial vessels with lumen 
diameter stenoses. 
The effects of minimal lumen diameter on subsequent 
clinical events, reocclusion and left ventricular function 
were analyzed by using logistic and linear egression analy- 
sis. In addition, on the basis of the retrospr. unpub- 
lished analysis of 90-min angiograms from the I-I and 
TAMI- trials, a trend toward more frequent reocclusion 
was noted when the infarct-related minimal lumen diameter 
was 11 .O mm. Therefore, to further analyze the predictors 
of in-hospital clinical events, reocclusion and recovery of 
left ventricular function, patients were dichotomized into 
those with a 90-min infarct-related minimal lumen diameter 
11.0 mm and those with an Infarct-related minimal lumen 
diameter >l.O mm. In addition, to evaluate the effect of 
delayed clot lysis on the recovery of left ventricular fucdion 
during the convalescent period, patients were also catego- 
rized into those with a 50.5mm change in the infarct-related 
minimal lumen diameter or those with a >0.5-mm change in 
minimal lumen diameter f om the 90-min to the 7-day arte- 
riogram. 
Quantitative left ventricular function analysis. Single- 
plane contrast left ventriculography was performed from the 
30” right anterior oblique projection. Global and regional 
wall motion analysis was performed by an observer who had 
no knowledge of the clinical outcome and the quantitative 
angiographic analysis. Ventricu1a.r contours from selected 
nonpostpremature end-diastoiic and end-systolic tine frames 
were hand drawn and digitized. By using a computer- 
assisted ventricular nalysis program, global left ventricular 
ejection fraction was determined with the area-length 
method (7); regional wall motion, expressed as the SD per 
r,hord, was determined with the method of Sheehan et al. (8). 
The 90-min and 7-day ventriculograms were analyzed, and 
the changes in global and regional left ventricular function 
Ventricnlographic analysis was not per- 
y beats available were post ature ven- 
exes, if inadequate contrast filling of the entire 
occurred or if s~g~i~~cant :~otiun ariifacr 
g the ventr~cn~ogram, 
The following in-hospital c inical evenis 
were obtained from the clinical case report form: 1) death; 
2) reinfarction, diagnosed by a second elevation of cardiac 
enzymes; 3? ~coccl~%n, defined angiogra 
rent ischemia, defined by >20 min of sym 
with myocardial ischemia ssociated with 
changes; 5) the need for coron angioplasty orcoronary 
bypass urgery before the plann -day catheterization; 2 d 
6) congestive heart failure, dia ed by radiographic pul- 
monary edema, rales more than bibasilar or requirement for 
analyses. Blood samples, collected on 
200 KIU/ml aprotinin at baseline and I, 4 
h after fibrinoiytic therapy, were immediately proc- 
essed and kept frozen at -20°C until assayed at the core 
y laboratory. Fibrinogen was determined by a 
n rate assay (9), and fibrinogen degradation prod- 
ucts were analyzed by the tanned red cell agglutination 
inhibition technique (IO). -dimer levels were ined 
with the method of Elms et al. (11). 
Statistical analysis. For descriptive presentation f the 
data, continuous baseline and treatment variables were 
summarized asmean values + SD, whereas discrete varia- 
bles were expressed as percentages. Sinary outcomes 
among the drug regimens were compared with conventional 
chi-square analysis. Similarly, continuous outcomes among 
the drug regimens were compared with use of the Kruskal- 
Wallis test. Univariable logistic regression was used to 
examine the relation between minimal lumen diameter at 
90 min and the occurrence of reocclusion and in-hospital 
events, The relation between minimal lumen diameter and 
left ventricular function was displayed with dichotomous cut 
points but also characterized with linear egression analysis. 
A p value ~0.05 was considered significant. 
Clinical characteristics. The clinical characteristics of pa- 
tients randomized to early cardiac atheterization a d to 
treatment with one of the three thrombolytic regimens have 
been reported previously (1). In general, these clinical 
features were similar in each of the three treatment groups 
(Table I), although more patients treated with t-t-PA were 
male and had a history of prior myocardial infarction. The 
infarct-related artery was most often the right coronary 
artery, followed in frequency by the left anterior descending 
and circumflex coronary arteries. Mean symptom duration 
was 3.2 2 1.9 h (range 1.1 to 7.4) before administration f 
thrombolytic therapy and was similar in the treatment 
groups. In-hospital c inical events and reocclusion were less 
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Table 1. Baseline Characteristics of Patients Receiving H-PA, -__._ _
Urokinase or Combination Thrombolytic Therapy 
rt-PA 
(Il = 95) 
Urokinase 
(II = 95) 
Combination 
(n = 97) 
Age (yr) 
Male (%I 
Prior MI (%E) 
Multivessel disease (%) 
Infarct-related artery (%) 
LAD 
LCX 
RCA 
Left main 
Unknown 
Symptom duration (hl 
Reocclusion (%I* 
56% II 57 + IO 58 + ,\I 
89 77 71 
22 8 12 
44 63 51 
36 38 42 
14 I5 8 
48 46 49 
I 0 0 
I I I 
3.S ” 2.8 3.0 + I.2 3.2 4 I.3 
I3 9 3 
Any in-hospital event I%# 38 32 25 
Data are presented as mean value ? SD or percent of subgroup. *p = 0.03. 
‘p = 0.084. LAD = IeR unlerior descending coronary artcry; L,Cx = lefl 
circumflex coronary arccry; MI = myocardial infarction: rt-PA = recombinant 
tissue-type plnsminogen uctivalor; RCA = right coronary artery. Adapted, 
with permission, from Califf et al. (I ). 
frequent in patients receiving combination thrombolytic 
therapy (1). 
Acute and convalescent infarct-related minimal lumen di- 
ameter, Compared with those receiving rt-PA or urokinase 
monotherapy, patients receiving combination rt-PA and 
urokinase had a slightly larger, but not significantly different, 
minimal lumen diametr ‘mmediately after initiation of 
thrombolysis (p = 0.16’ Ye 2). Minimal lumen diameter 
was independent of the location of the infarct-related artery 
and symptom duration. Minimal lumen diameter at 7 days 
also was similar in the three treatment groups. Notably, the 
change in minimal lumen diameter from the 90.min to the 
l-day studies also did not vary by combination versus 
monotherapy treatment regimen. 
Hemostatic protein levels. Patients receiving urokinase 
and combination rt-PA and urokinase had significantly lower 
I-h, 4-h, 24-h and nadir fibrinogen levels compared with 
those of patients receiving rt-PA (Table 3). Similarly, I-h, 
4-h, 24-h and peak fibrinogen degradation products and 
D-dimer levels were significantly higher in patients receiving 
urokinase and combination rt-PA and urokinase than in 
those receiving rt-PA monotherapy. 
Angiographic and hemostatic correlates of in-hospital clin- 
ical events and reocclusion. Although patients with in- 
hospital clinical events had a somewhat smaller 90-min 
infarct-related minimal lumen diameter, these values were 
not significantly different from that of patients without such 
events (0.64 r 0.52 mm vs. 0.72 f 0.53 mm; p = 0.26). 
Furthermore, in the subgroup of patients with angiographi- 
tally documented coronary reocclusion, infarct-related min- 
imal lumen diameter was similar to that in patients without 
subsequent reocclusion (0.70 5 0.52 vs. 0.68 2 0.59; p = 
0.87). Baseline, peak and nadir hemostatic protein concen- 
trations did not correlate with acute minimal lumen diameter 
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Table 2. Minimal Lumen Diameter After H-PA, Urokinase or 
Combination Thrombolytic Therapy 
-. 
&PA Urokinase Combination 
% Patency 
MLDw, n>in (mm) 
By IRA 
LAD 
LCX 
RCA 
By symptom-onset 
~2 h 
2to4h 
>4 II 
MLDl,;,, , (mm) 
AMLD,, 1,,,n-7 ,,;,, (mm) 
By IRA 
LAD 
L,; 
RCA 
76 (68189) 73 (67192) 
0.72 + 0.45 0.62 + 0.53 
(86) (88) 
0.81 + 0.46 
(30) 
0.51 -L 0.34 
(I!) 
0.72 4 0.47 
(43) 
0.59 r 0.55 
(35) 
0.47 ? 0.38 
(12) 
0.68 c 0.56 
(41) 
0.66 + 0.54 
(18) 
0.74 + 0.40 
(46) 
0.73 + 0.50 
(22) 
1.0s I 0.56 
(57) 
0.22 f 0.55 
(55) 
0.66 ? 0.62 
(17) 
0.62 i: 0.53 
(55) 
0.54 c 0.46 
(I61 
I.12 jl 0.72 
(54) 
0.30 a 0.69 
02) 
0.14 + 0.34 
(18) 
0.43 2 0.98 
(6) 
0.22 I 0.57 
(30) 
0.39 ?; 0.80 
(18) 
0.13 + 0.21 
(61 
0.28 + 0.68 
128) 
77 (70/91) 
0.75 _+ 0.58 
(85) 
0.67 4 0.48 
(37) 
0.93 2 0.57 
(6) 
0.80 ?r 0.66 
(42) 
0.63 + 0.44 
(15) 
0.80 f 0.61 
(51) 
0.71 t (I.59 
(I’)) 
0.94 1 0.s4 
(65) 
0.08 + 0.42 
161) 
0.07 f 0.37 
(29) 
-0.12 + 0.45 
(6) 
0.15 + 0.46 
(26) 
Data are expressed as percent of subgroup or mean value ? SD with the 
number of patients in parentheses. AMLD = change in minimal lumen 
diameter; IRA = infarct-related artery: MLD = minimal lumen diameter: 
other abbreviations as in Table I. 
(Table 4). However, baseline and nadir fibrinogen levels 
directly correlated and peak fibrinogen degradation products 
indirectly correlated with angiographically documented re- 
occlusion. 
Correlates of recovery of left ventricular function. By 
linear regression analysis, a direct correlation between the 
infarct-related minimal lumen diameter and regional wall 
motion at 90 min (p = 0.021) was noted, although no other 
relations were found between 90-min or ‘i-day minimal 
lumen diameter and 90.min or 7-day global or regional left 
ventricular function. Values for 90-min and ‘I-day global left 
vell’ricular function and infarct-zone regional wall motion 
were also comparable in patients with a 90.min infarct- 
related minimal lumen diameter 5-1 mm and in those with 
minimal lumen diameter >I mm (Table 5). The 90-min 
infarct-related minimal lumen diameter was identical 
(0.8 mm) in patients with a fina! left ventricular ejection 
fraction SO.40 or BO.40. 
Alterations in hemostatic protein concentrations. In pa- 
tients with acute myocardial infarction, combination therapy 
&PA 
b-i = 9% 
Fibrinogen (g/liter) 
Baseline 
I 
4 
24 
Nadir* 
FDP (pgiml 1 
Baseline 
1 
4 
24 
Peak* 
D-dimcr (@ml) 
Baseline 
I 
4 
24 
Peak* 
3.36 t 2.48 
2.91 2 1.15 
1.90 It 0.96 
2.90 2 3.55 
1.90 T 0.86 
20 t 33 
414 + 880 
375 ? 656 
156 2 306 
435 t 717 
152 1 186 
565 _+ 392 
1.073 _+ 1.344 
796 t 1,132 
I.091 _+ 1.333 
2.88 ?z 0.96 3.13 ? P.02 
0.98 i 0.58 0.78 -L 0.61 
0.77 rt 0.61 0.69 r I)._54 
9.46 2 0.50 1.51 5 0.61 
0.75 I: 0.53 3.85 r 1.00 
244 -t 439 
908 t- 623 
992 + 644 
713 I632 
1.031 z 756 
19 I 53 
I.365 i: I.025 
1.325 + 840 
4X6 t 559 
I.307 ?. 860 
I86 t 279 
745 t 682 
I.!hl L $16 
R41 + SH5 
i.271 +_ 842 
Values are expressed as mean value + SD. *p < 0,001 compared with 
baseline levels. FDP = fibrin degradation products: U-PA = recombinan! 
tissue-type pjasminogen activator. 
with rt-PA and urokinase has been shown to reduce in- 
hospital clinical ischemic events more effectiveiy than Ras 
either agent administered alone (I). wever, the mecha- 
nism responsible for the favorable c 
tients receiving combination thrombolytic therapy has re- 
mained somewhat elusive. Infarct-related artery patency 
rates and recovery of left ventricular function have been 
shown to be equivalent using single-agent and combination 
thrombolytic strategies (L-3). Similarly, in the present study, 
quantitative angiographic analysis of infarct-related coro- 
nary artery dimensions in287 patients failed to demonstrate 
that the lower in-hospital clinical event rate observed in 
patients receiving combination thrombolytic therapy re- 
sulted from more extensive early or late coronary thrombol- 
ysis. Notably, patients receiving combination rt-PA and 
urokinase and urokinase monotherapy had more profound 
depletion of fibrinogen and larger production of fibrinogen 
degradation products and D-dimer than did patients receiv- 
ing rt-PA monotherapy. These alterations in hemostatic 
protein concentrations were correlated with angiographi- 
tally documented reocclusion, suggesting that lower clinical 
cal” residual stenosis generally 
on. In the absence of reoc~I~sio~, the
residual coronary stenosis may improve progrsssively dur- 
the convalescent period (6,86,i8,20), asa result of both 
mbus ~~ss~~ut~~~ and remodeling of the atherosclerotic 
tissue-type plasminogen activator ( 
fibrin-selective thrombolytic agents (22) may be more 
tive than nonselective agents in 
ret-related artery recanalization. 
~in~se~ect~ve agents 
may occur in 12% 
concomitant therapy with aspirin nd heparin (23). Fibrin- 
nonselective agents, such as stre 
may be less effective in establis 
recanalization, but they are associated with less frequent late 
reocclusion, owing, in part, to more profound effects on 
hemostatic protein levels resulting from systemic fil;rinoly- 
sis. As a result of s “catch-up” pnenomen 
patency rates with in-selective and nonsele 
have been shown 24 h after administration f thromboiytic 
agents (22). 
The differential effects on early infarct-related artery 
recanalization a d reocclusion of fibrin selective and non- 
selective agents have led some to suggest that combination 
thrombolytic administration may be more effective than 
monotherapy in establishing early and sustained infarct- 
related artery recanalization (L-3). Combined use of a fibrin- 
selective agent such as rt-PA and a fibrin-nonselective ag nt 
xch as urokinase may result in more timely and sustained 
thrombolysls than could be achieved by either agent alone. 
No prior studies have used quantitative angiography asthe 
reference standard toexamine the effects of combination a d 
monotherapy regimens on the magnitude ofclot lysis. 
In this report, infarct-related artery patency rates and 
Table 4. Effect of Hemostatic Protein Levels on Weocclusion and Minimal Lumen Diameter at 90 Minutes 
- 
Reocclusion* Minimal Lumen Diameter at 90 Minutest 
Relation Chi-Square p Value Relation Chi-Square p Value 
Fibrinogeneaseline Direct 4,% 0.026 Direct 0.036 0.85 
FibrinogenNadir Direct 2.90 0.089 lndirec: 0.146 0.70 
FDPneseane Indirect 0.92 0.340 Indirect 0.490 0.48 
PDPPcak Indirect 8.10 0.004 Direct 0.751 0.39 
*Logistic regression analysis. tLinear regression analysis. FDP = fibrin degradation producls. 
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Table 5. Effect of the Extent of Thrombolysis on Left Ventricular Function 
Minimal Lumen Diameter at 90 Minutes A in Minimal Lumen Diameter 
51.0 mm >I.0 mm SO.5 mm >0.5 mm 
90 min 
LVEF 53.3 + 12.9 (156) 51.9 f 14.1 (41) - - 
Infarct zone RWM -2.61 + 1.01 (156) -2.53 i: I.12 (41) - - 
Noninfarct zone RWM 0.24 + 1.77 (156) 0.39 ?I I.91 (41) - 
7 days 
LVEF 55.0 2 I I .8 (107) 53.5 ?r 14.5 (43) 55.0 ? 12.4 (I??) 51.7 5 13.4 (25) 
Infarct zone RWM -2.06 + 1.24 (107) -2.03 + 1.29 (43) -1.99 2 I.28 (122) -2.42 2 1.03 (25) 
Noninfarct zone RWM 0.12 -’ 1.32 (107) 0.18 5 1.43 (43) O.S8 i: 0.94 (93) 0.19 + 0.84 (22) 
A 
A LVEF 0.6 + 7.3 (87) 2.2 + 8.1 (31) 1.8 5 7.4 (Y3) -2.9 i: 7.0 (22) 
A Intkct zone RWM 0.44 + 0.97 (87) 0.74 9 0.80 (31) 0.58 i: 0.!!4 (93) 0.19 -” 0.84 (22) 
A Noninfarct zone RWM -0. I2 P 0.97 (87) -0.16 + I.06 (31) -0.03 I? O.Y7 (93) -0.66 2 0.98 (22) 
Data arc expressed as mean value I SD with the number of patients in parentheses. A = ch;mge from 90 min to 7 day>: LVEF = left ventricular ejection 
fraclion (%); RWM = regional wall motion (SD/chord). 
values for ,esidual minimal lumen diameter did not dialer 
significantly early after the administration f rr-PA, uroki- 
nase or combination rt-PA and urokinase. Minimal umen 
diameter in this study was similar to that obtained in 
previous reports with use of intracoronary streptokinase (6) 
and after a 40.mg intravenous infusion of r&PA (16). Im- 
provements in minimal lumen diameter (0.3 to 0.5 mm during 
the %day convalescent period) were also similar to those 
seen after t-PA monotherapy (16) and were not significantly 
different among the patients treated with combination versus 
monotherapy. These data suggest that he degrees of initial 
and delayed clot lysis, as determined by quantitative angio- 
graphic methods, are similar whether patients are treated 
with single-agent rt-PA or urokinase or with combination 
rt-PA and urokinase. 
Angiographic and hemostatic protein correlates of in- 
hospital clinical events and reocclusion. Recurrent ischemic 
events including coronary reocclusion occur in up to 21% of 
patients after successful thrombolysis with rt-PA (12) and 
are often associated with significant in-hospital morbidity 
and mortality (23). Smaller series have suggested that the 
residual lumen diameter after thrombolytic therapy may be 
an important determinant of risk for recurrent ischemic 
events (17,24,25). However, in a report by Ellis et al. (12) of 
190 patients with angiographically documented successful 
thrombolysis qualitative morphometric and quantitative 
angiographic variables were not useful in predicting in- 
hospital ischemic events. In the present study of nearly 300 
patients, quantitatively determined infarct-related minimal 
lumen diameters were also of no help in predicting either 
in-hospital c inical events or angiographically documented 
reocclusion. 
Experimental studies uggest that recurrent thrombosis 
after thrombolysis may occur principally as a consequence 
ofrecurrent platelet aggregation a d thrombosis atthe site of 
the residual coronary stenosis (26-28). In these models 
reocch&ion was prevented orat least ameliorated byspecific 
platelet inhibition (27,28). Alterations of hemostatic protein 
levels may also influence reocclusion after thrombolysis. In 
a series of 386 patients receiving IS0 mg of r&PA, peak 
fibrinogen degradation products (p = 0.038) and changes in 
fibrinogen levels from baseline to nadir (p = 0.0003) were 
indirectly correlated with reocclusion (29). N 
tativc blood loss was also correlated with na 
levels and peak fibrinogen degradation products. Systemic 
fibrinogen degradation appears to be less extensive with 
lower doses of rt-PA; ~15% of patients develop fibrinogen 
levels ~1 g/l when the currently approved ose of 100 mg of 
t-t-PA is administered (3). 
In the present study, patients treated with combination 
thrombolytic therapy or urokinase monotherapy had signif- 
icantly lower nadir fibrinogen levels and higher fibrinogen 
degradation products than did patients treated with rt-PA 
monotherapy. Peak fibrinogen degradation products were 
indirectly related to angiographic reocclusion, suggesting 
that extensive systemic fibrinogen degradation may have 
been responsible for the lowered clinical event rates and 
lower ates of reocclusion observed with combination ther- 
apy. Similar to a prior report (29), no relation was noted 
between alterations inhemostatic protein levels and reper- 
fusion, assessed inthe present report by quantitative angio- 
graphic methods. 
Correlates of early and ‘I-day left ventricular function. 
Several factors, including baseline left ventricular function 
(30). time to reperfusion (31) and infarct-related artery 
patency (32), have been related to the recovery of left 
ventricular function after myocardial infarction. At least two 
prior studies (14,33) have suggested that severity of the 
residual stenosis may be an important determinant d subse- 
quent recovery of left ventricular function. In a series of 38 
patients receiving intracoronary streptokinase, r sidual min- 
imal lumen diameter after successful reperfusion was 
CO.4 mm in 7 patients and 20.4 mm in 31 (14). Recovery of 
regional wall motion was significantly less in patients with a 
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of the residual steno- 
beneficial effect on ventricular function (34,35). 
ysis of global eft ventricular function 
otion was available in 
convalescent phase of myocard~a~ infarc 
study. As assessed by both continuous 
outcome measures, only early mi~i~ial 1 
correlated with early infarct-zone r gional wail emotion (p= 
0.021). Notably, neither early acute nor convalescent mini- 
mal lumen diameter was correlated with the recovery of 
vcntricdar f~~~c~~~~. dia 
r&r in patients witl nt 1 
ventricular ejec;ton fraction of zz or >0.40. These findings 
support previous data (14,30,32) suggesting that the critical 
determinant of -ecovery ot ventricufar function is coronary 
repeufusion, with the extent of clot lys;s sod severity of 
The present analysis has several 
limitations. First, the angiographic criterion used to assess 
the degree of clot lysis, the minimal lumen diameter, may 
incompletely represenr the geometric resolution ofcoronary 
thrombus in patients with acute myocardial infarction. For 
example, changes in stenosis area (16) may provide a more 
accurate representation f the degree of clot lysis, but this 
cult to apply to a single 90-min arteriogram, 
particularly when the lesion length is not precisely known. 
Second, the use of automated edge detection analysis of 
digitized arteriograms ay be of limited iscriminating value 
in lesions with a minimal lumen diameter cl.0 mm (36). 
Nevertheless, the use of the quantitatively determined end 
point in the present study should have demonstrated some 
beneficial effect if combination thrombolytic therapy istruly 
more effective in lysing thrombus. Technically adequate 
ventriculographic analysis was available in approximately 
60% of patients receiving thrombolytic therapy; exclusions 
were most commonly due to difficulties in obtaining a 
ventriculogram suitable for quantitative analysis. Moreover, 
because of the effects of noninfarct zone hyperkinesia and 
late potential prognostic mportance of left ventricular re- 
modeling, left ventricular ejection fraction may not be the 
optimal end point for the clinical evaluation of left ventric- 
ular function (37). Finally, front-loading rt-PA regimens 
(infusion over 90 min) have been associated with higher 
patency rates than have the standard 3-h infusions of r&PA 
(38). Whether added clinical benefit over that of front-loaded 
r-t-PA monotherapy is achieved by using combination throm- 
d urokinase. h-l-m clinical events, reocc~~s~o~ 
e of~~~tia~ and late dot 
in patients receiving 
tial or late ciot lysis. 
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